Maulik Zaveri, MD
Cornea and External Diseases Specialist · Vista, CANPI 1780848937
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 216 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 27 manufacturers reported payments, led by Alcon at 39.9% of the total.
Across 216 payments — averaging $29.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$3K
- AbbVie$583
- NEW World Medical,inc.$492
- Glaukos Corporation$399
- Mallinckrodt Hospital Products Inc.$348
- Tarsus Pharmaceuticals, Inc.$250
- plus $2K from 21 others
What the payments were for
- Travel & lodging$150%
- Food & beverage$6,406100%
- Entertainment$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 69 | $2,566 |
| AbbVie(2 entities) | 33 | $583 |
| NEW World Medical,inc. | 4 | $492 |
| Glaukos Corporation | 7 | $399 |
| Mallinckrodt Hospital Products Inc. | 17 | $348 |
| Tarsus Pharmaceuticals, Inc. | 9 | $250 |
| Novartis | 12 | $238 |
| Harrow Eye, LLC | 7 | $221 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 15 | $187 |
| Biotissue Holdings Inc. | 2 | $170 |
| Johnson & Johnson Surgical Vision, Inc. | 4 | $134 |
| Rxsight Inc | 1 | $125 |
| Kala Pharmaceuticals, Inc. | 5 | $112 |
| Bausch & Lomb Americas Inc. | 6 | $109 |
| Oyster Point Pharma, Inc. | 4 | $86 |
| Shire North American Group Inc | 4 | $85 |
| Aerie Pharmaceuticals, Inc. | 5 | $83 |
| Sun Pharmaceutical Industries Inc. | 2 | $37 |
| Ocular Therapeutix, Inc. | 2 | $28 |
| Amgen | 1 | $28 |
| Dompe US, Inc. | 1 | $28 |
| Alcon Research LLC | 1 | $26 |
| Lombart Brothers, Inc. | 1 | $24 |
| Thea Pharma Inc. | 1 | $24 |
| Eyevance Pharmaceuticals LLC | 1 | $18 |
| Sight Sciences, Inc. | 1 | $18 |
| Optos, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,435 in reported general payments places this provider in the 60th percentile of 50 cornea and external diseases specialist providers in California.
See all cornea and external diseases specialist providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 279 | $160,703 |
| RestasisCyclosporine | 33 | $48,445 |
| XiidraLifitegrast | 27 | $35,223 |
| IlevroNepafenac | 80 | $29,531 |
| MieboPerfluorohexyloctane/Pf | 39 | $28,901 |
| Alphagan PBrimonidine Tartrate | 50 | $16,092 |
| ProlensaBromfenac Sodium | 44 | $14,541 |
| Prednisolone Acetate | 373 | $14,260 |
| RhopressaNetarsudil Mesylate | 15 | $10,972 |
| Latanoprost | 640 | $10,828 |
| Cyclosporine | 19 | $10,478 |
| VyzultaLatanoprostene Bunod | 15 | $8,902 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 38 | $6,980 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 25 | $6,337 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 17 | $5,340 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Alphagan P | $583 | $225,241362 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo, Vyzulta | $109 | $73,02581 claims |
| NovartisIlevro | $238 | $29,53180 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Loteprednol Etabonate | $187 | $16,41956 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa | $83 | $10,97215 claims |
| AlconSimbrinza | $2,566 | $6,33725 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 50 cornea and external diseases specialist providers in California.
Other cornea and external diseases specialist in Vista
- Sumit GargIrvine$808K
- Jillian ChongBeverly Hills$113K
- Tyson KimSan Francisco$91K
- Edward MancheStanford$78K
- Michael SavetskyCulver City$63K
- Michael SaidelSonoma$51K
- Matthew WadeIrvine$38K
- Lawrence ChaoIrvine$36K
- William ChristianSanta Monica$33K
- Alexander FosterEncinitas$29K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.